Essential CNS drug development / (Record no. 520930)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03281nam a22003258i 4500 |
| 001 - CONTROL NUMBER | |
| control field | CR9780511977640 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | UkCbUP |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20200124160309.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
| fixed length control field | m|||||o||d|||||||| |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 101013s2012||||enk o ||1 0|eng|d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780511977640 (ebook) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9780521766067 (hardback) |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | UkCbUP |
| Language of cataloging | eng |
| Description conventions | rda |
| Transcribing agency | UkCbUP |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.25 |
| Item number | .E82 2012 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1/9 |
| Edition number | 23 |
| 245 00 - TITLE STATEMENT | |
| Title | Essential CNS drug development / |
| Statement of responsibility, etc | edited by Amir Kalali [and others]. |
| 264 #1 - Production, Publication, Distribution, Manufacture, and Copyright Notice (R) | |
| Place of production, publication, distribution, manufacture (R) | Cambridge : |
| Name of producer, publisher, distributor, manufacturer (R) | Cambridge University Press, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (x, 207 pages) : |
| Other physical details | digital, PDF file(s). |
| 336 ## - Content Type (R) | |
| Content type term (R) | text |
| Content type code (R) | txt |
| Source (NR) | rdacontent |
| 337 ## - Media Type (R) | |
| Media type term (R) | computer |
| Media type code (R) | c |
| Source (NR) | rdamedia |
| 338 ## - Carrier Type (R) | |
| Carrier type term (R) | online resource |
| Carrier type code (R) | cr |
| Source (NR) | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Title from publisher's bibliographic system (viewed on 05 Oct 2015). |
| 505 00 - FORMATTED CONTENTS NOTE | |
| Title | History of CNS drug development / |
| Statement of responsibility | Sheldon H. Preskorn -- |
| Title | Regulatory issues / |
| Statement of responsibility | Gwen L. Zornberg -- |
| Title | Essential CNS drug development : pre-clinical development / |
| Statement of responsibility | Alan J. Cross and Frank D. Yocca -- |
| Title | Phase I trials : from traditional to newer approaches / |
| Statement of responsibility | Matthew Macaluso, Michael Krams and Sheldon H. Preskorn -- |
| Title | Phase II development and the path to personalized medicine in CNS disease / |
| Statement of responsibility | Douglas E. Feltner and Kenneth R. Evans -- |
| Title | CNS drug development : Phase III / |
| Statement of responsibility | Judith Dunn, Penny Randall and Amir Kalali -- |
| Title | Statistics issues relevant to CNS drug development / |
| Statement of responsibility | Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs -- |
| Title | Clinical trials management at company level / |
| Statement of responsibility | Nuala Murphy -- |
| Title | Clinical trials management at the site level / |
| Statement of responsibility | Joseph Kwentus -- |
| Title | Medical writing for CNS indications / |
| Statement of responsibility | Ginette Nachman -- |
| Title | Dissemination of clinical trial information : multiple audiences, multiple formats / |
| Statement of responsibility | Leslie Citrome -- |
| Title | The importance of treating cognition in schizophrenia and other severe mental illnesses : background, strategies, and findings to date / |
| Statement of responsibility | Philip D. Harvey and Richard S.E. Keefe -- |
| Title | Leveraging disruptive technologies to drive innovation in CNS clinical drug development / |
| Statement of responsibility | Penny Randall, Judith Dunn and Amir Kalali. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Central nervous system stimulants |
| General subdivision | Development. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kalali, Amir, |
| Relator term | editor. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Print version: |
| International Standard Book Number | 9780521766067 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1017/CBO9780511977640">https://doi.org/10.1017/CBO9780511977640</a> |
No items available.